Table 3.
Subgroup analysis of the effectiveness of the third vaccine dose versus two vaccine doses of the BNT162b2 mRNA COVID-19 vaccine
| Total number in analysis (both study groups combined) |
Vaccinated with two doses |
Vaccinated with three doses |
1 – risk ratio (95% CI) | Risk difference per 100 000 individuals (95% CI) | ||||
|---|---|---|---|---|---|---|---|---|
| Events | Risk per 100 000 individuals | Events | Risk per 100 000 individuals | |||||
| Admissions to hospital | ||||||||
| Sex | ||||||||
| Male | 458 552 | 140 | 321·6 | 21 | 25·2 | 92% (85 to 97) | 296·4 (177·2 to 443·2) | |
| Female | 483 548 | 91 | 132·1 | 8 | 5·0 | 96% (93 to 99) | 127·1 (87·2 to 175·9) | |
| Age group, years | ||||||||
| 16–39 | 288 072 | 6 | 7·0 | 1 | 2·1 | 70% (−70 to 100) | 4·9 (−2·1 to 12·3) | |
| 40–69 | 448 366 | 73 | 104·9 | 10 | 8·1 | 92% (83 to 97) | 96·7 (60·1 to 148·7) | |
| ≥70 | 162 958 | 140 | 574·3 | 16 | 41·3 | 93% (87 to 97) | 533·0 (390·1 to 675·3) | |
| Number of coexisting conditions | ||||||||
| 0 | 462 690 | 14 | 13·4 | 2 | 1·5 | 89% (60 to 100) | 11·9 (4·3 to 22·3) | |
| 1–2 | 336 850 | 61 | 111·5 | 7 | 9·7 | 91% (80 to 98) | 101·9 (61·9 to 145·9) | |
| ≥3 | 142 560 | 156 | 689·7 | 20 | 56·3 | 92% (87 to 96) | 633·4 (456·4 to 847·7) | |
| Severe disease | ||||||||
| Sex | ||||||||
| Male | 458 652 | 103 | 233·0 | 13 | 24·8 | 89% (73 to 98) | 208·2 (109·7 to 343·9) | |
| Female | 483 614 | 54 | 93·2 | 4 | 2·8 | 97% (93 to 99) | 90·4 (57·4 to 137·8) | |
| Age group, years | ||||||||
| 16–39 | 288 086 | 2 | 2·5 | 0 | 0·0 | NA | 2·5 (0·7 to 7·5) | |
| 40–69 | 448 410 | 38 | 57·9 | 5 | 3·5 | 94% (85 to 99) | 54·4 (28·0 to 87·6) | |
| ≥70 | 163 054 | 108 | 447·5 | 10 | 35·8 | 92% (83 to 98) | 411·7 (285·9 to 548·7) | |
| Number of coexisting conditions | ||||||||
| 0 | 462 706 | 5 | 3·1 | 0 | 0·0 | NA | 3·1 (0·7 to 6·0) | |
| 1–2 | 336 902 | 39 | 82·0 | 2 | 3·2 | 96% (85 to 100) | 78·8 (39·3 to 126·8) | |
| ≥3 | 142 658 | 113 | 503·5 | 15 | 51·6 | 90% (80 to 96) | 451·9 (322·3 to 605·2) | |
Estimates were obtained using the Kaplan-Meier estimator starting from day 7 after receipt of the third dose in those who received it. Data are listed as NA when one or both of the study groups do not have any events. NA=not available.